ESC 23: ARAMIS: Anakinra versus Placebo in Acute Myocarditis

Published: 28 Aug 2023

  • Views:

    Views Icon 131
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

ESC 23 - We are joined onsite by Dr Mathieu Kerneis (Pitie Salpetriere APHP University Hospital, FR) and Dr Gilles Montalescot to discuss the findings from the ARAMIS trial (NCT03018834).

ARAMIS was the largest randomised controlled trial of acute myocarditis. The study included 120 hospitalised, symptomatic patients with increased cardiac troponin and diagnosed acute myocarditis using cardiac magnetic resonance imaging. They were randomly allocated 1:1 to recieve either a daily subcutaneous dose of anakinra 100mg, or placebo until their discharge from hospital.

Results showed that anakinra was safe, but did not reduce the complications of acute myocarditis.

1. What is the prognosis of acute myocarditis?
2. What is the study drug?
3. What is the study design and patient population?
4. What are the key findings presented at ESC 2023?
5. What are the next steps? 

Recorded on-site at ESC Congress 2023, Amsterdam. 

For more content from ESC Congress 2023 head to the Hot Line & Late-breaking Science Video Collection.

Editors: Mirjam Boros and Jordan Rance
Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles


You must be to comment. If you are not registered, you can register here.